07:00 , Jun 18, 2012 |  BioCentury  |  Finance

Analyst tracks

Analyst tracks Jason Kolbert joined Maxim Group as SVP of biotechnology research. He was VP of business development at NeoStem Inc. (NYSE-A:NBS). Adam Cutler departed from Credit Suisse, where he was a director and senior biotechnology analyst....
07:00 , Oct 26, 2009 |  BC Week In Review  |  Financial News

GlycoMimetics completes venture financing

GlycoMimetics Inc., Gaithersburg, Md.   Business: Inflammation, Infectious   Date completed: 10/21/09   Type: Venture financing   Raised: $38 million   Investors: New Enterprise Associates; Genzyme Ventures; Anthem Capital; Alliance Technology Ventures   ...
00:45 , Oct 22, 2009 |  BC Extra  |  Financial News

GlycoMimetics raises $38 million

GlycoMimetics Inc. (Gaithersburg, Md.) raised $38 million in a series C round led by New Enterprise Associates. Genzyme Ventures, a new investor, and existing investors Novartis Venture Funds; Anthem Capital; and Alliance Technology Ventures also...
02:03 , Jan 30, 2009 |  BC Extra  |  Financial News

Garnet raises $10.4 million

Garnet (Malvern, Pa.) raised $10.4 million in a private round led by SCP Vitalife Partners. Safeguard Scientifics and Alliance Technology Ventures also participated. Garnet's human adult bone marrow-derived cell therapy is in Phase II testing....
07:00 , Aug 6, 2007 |  BioCentury  |  Finance

Ebb & Flow

With all the big names accounted for in the 2Q07 earnings season, the Street has rendered its verdict on the prospects going forward, punishing big pharma while giving big biotech at least the benefit of...
23:48 , Jun 23, 2006 |  BC Extra  |  Financial News

GlycoMimetics raises $15.4 million

Inflammation and infectious company GlycoMimetics (Gaithersburg, Md.) raised $15.4 million in a series B round led by New Enterprise Associates. Existing investors Alliance Technology Ventures; Anthem Capital; Novartis Venture Fund; PTV; and the Maryland Department...
07:00 , Aug 15, 2005 |  BioCentury  |  Finance

Ebb & Flow

Last week's IPO by Coley (COLY) was the first U.S. biotech IPO to price at the top of the range and then trade up in the aftermarket since small molecule company Theravance (THRX) in October...
01:16 , Aug 11, 2005 |  BC Extra  |  Financial News

Genoptix raises $17.3 million

Genoptix (San Diego, Calif.) raised $17.3 million in a series D round. Investors included Chicago Growth Partners; Enterprise Partners; Alliance Technology Ventures; Tullis-Dickerson; U.S. Trust; and Lotus BioScience. Chicago Growth's Arda Minocherhomjee joined Genoptix's board....
07:00 , Aug 16, 2004 |  BioCentury  |  Finance

Ebb & Flow

Investors reacted badly to Monday's post-market news that Barr (BRL) will receive a license from Cephalon (CEPH) to sell generic oral transmucosal fentanyl starting Feb. 3, 2007. CEPH was off $4.86 (10%) to $43 on Tuesday...
08:00 , Mar 8, 2004 |  BioCentury  |  Finance

Ebb & Flow

With two months of the year already gone, the trends are saying that the IPO window is helping to open venture purse strings. In the U.S., private companies raised $641 million to the end of...